Celiac Disease Drug Pipeline — PatSnap Eureka
Celiac Disease Drug Pipeline: TG2 Inhibitors, IL-15 Blockade & Gluten Detoxification
Celiac disease affects approximately 1% of Western populations with a lifelong gluten-free diet as the only standard of care. Discover the patent-driven innovation landscape spanning 12 distinct mechanistic approaches — from TG2 inhibition to engineered microbial therapeutics.
Three Molecular Targets Driving the CeD Drug Pipeline
Celiac disease (CeD) is a chronic T cell–mediated autoimmune enteropathy triggered by dietary gluten in genetically susceptible HLA-DQ2/DQ8-positive individuals. Tissue transglutaminase 2 (TG2) is the central enzymatic autoantigen — it deamidates glutamine residues in partially digested gluten-derived peptides (gliadin, glutenin, hordein, secalin), converting them into high-affinity ligands for HLA-DQ2.5 and HLA-DQ8 molecules on antigen-presenting cells. This deamidation step is prerequisite for activation of disease-specific CD4+ effector memory T cells in the lamina propria.
Anti-tTG2 autoantibodies are established serological biomarkers of active disease, and TG2 serves simultaneously as a druggable enzyme and as the primary autoantigen. The PatSnap analytics platform reveals that retrieved results highlight three principal molecular targets driving the contemporary drug pipeline: TG2 itself, IL-15, and the HLA-DQ2.5/DQ8 antigen presentation axis.
IL-15 is overexpressed in both lamina propria and intestinal epithelium of active CeD patients, correlated with mucosal damage severity. Mouse models with intestinal epithelial IL-15 overexpression recapitulate a celiac-like enteropathy. The World Health Organization and National Institute of Allergy and Infectious Diseases recognize celiac disease as a significant autoimmune burden with no approved pharmacotherapy beyond dietary management.
Additional targets identified in this dataset include SMAD7/TGF-β signaling (Nogra Pharma), KIR3DL2 on innate T cells (Innate Pharma), JAK kinases (University of California), the aryl hydrocarbon receptor (AhR) pathway, and intestinal permeability mediators including zonulin/CXCR3. Explore the full patent landscape with PatSnap Eureka's AI-powered search.
12 Mechanistic Approaches Across the Celiac Disease Pipeline
From upstream TG2 enzyme inhibition to engineered microbial therapeutics, the retrieved patent landscape reveals a rich multi-modal innovation environment — predominantly commercially driven, with academic institutions concentrated in diagnostics.
TG2 Inhibitors — Mechanistically Targeted Upstream Blockade
TG2 inhibition is the most mechanistically specific pharmacological approach in the retrieved dataset. Dr. Falk Pharma GmbH (WO, 2025) discloses a personalized TG2 inhibitor regimen stratified by HLA-DQ haplotype. Transcriptomic analysis in a gluten challenge model showed that 100 mg/day of "Compound 1" effectively suppressed virtually all gluten-induced mucosal gene expression changes. The University of Debrecen (EP, 2018) covers diagnosis and treatment targeting the celiac-specific epitope on the transglutaminase family. Learn more about life sciences IP analytics for autoimmune targets.
Preclinical → Early Clinical (Falk Pharma 2025)Anti-IL-15 Antibodies — Most Jurisdictionally Expansive IP Estate
Amgen Inc. holds the dominant IP position with at least 6 patent filings across US, CA, WO, AU, EP, IN, MX jurisdictions (2017–2024), covering CeD, RCD Types I & II, and non-celiac gluten sensitivity (NCGS). The EP filing explicitly discloses dosing regimens of 4–16 mg/kg administered in 1–6 unit doses at 1–12 week intervals. Cephalon Inc. (Teva) holds active EP and WO filings for anti-IL-15 antibody DISC0280, which binds both free IL-15 and the IL-15/IL-15Rα complex — a mechanistically distinct epitope from Amgen's approach.
Clinical-Stage Signals (Active MX 2024)Peptide Immunotherapy — Five Assignees, Multiple Delivery Routes
Multiple assignees pursue tolerogenic peptide vaccination targeting HLA-DQ2/DQ8-restricted gluten epitopes. Immusant Inc. discloses a three-peptide combination (DQ2-α-I, DQ2-α-II, DQ2-α-III epitopes) in filings across EP, NZ, HU, IN, WO, US (2011–2016). BTG International covers transglutaminase-deamidated 20-mer epitopes for DQ2 and DQ8 patients. DBV Technologies (WO, 2025) introduces epicutaneous skin patch delivery of gliadin epitopes — a novel route leveraging the skin-gut immune axis. Explore PatSnap's IP analytics for epitope coverage mapping.
Active Clinical Investigation (Immusant CCL20 data)Microbial IL-10 + Antigen Co-Delivery — Broadest Multi-Jurisdictional Filing
Intrexon Actobiotics NV (Precigen ActoBio) holds the broadest multi-jurisdictional patent family in this dataset: WO, CA, IN, AU, US, JP, KR, CN filings from 2021–2023 covering genetically engineered Lactococcus lactis that chromosomally co-expresses IL-10 and CeD-specific gliadin antigens (HLA-DQ2/DQ8 epitopes, including deamidated forms). The named strain SAGX0868 (AU filing) delivers dual local immunosuppression and antigen-specific tolerance induction following oral administration.
Advanced Preclinical → Clinical (8 jurisdictions)Key Data Signals from the Celiac Disease Patent Landscape
Patent-derived metrics revealing the relative IP intensity, clinical-stage signals, and target distribution across the CeD drug pipeline.
Amgen Anti-IL-15 Dosing Regimen Parameters (EP Filing)
The Amgen EP patent explicitly discloses dosing of 4–16 mg/kg in 1–6 unit doses at 1–12 week intervals — parameters consistent with clinical-stage antibody development for CeD and RCD.
HLA Haplotype Distribution in CeD Patients
Approximately 90% of CeD patients carry HLA-DQ2 and 5–10% carry HLA-DQ8, as cited across multiple retrieved patents. These restriction elements determine which deamidated gliadin peptides are immunogenic.
IP Activity by Therapeutic Modality — Key Assignees
Relative patent filing intensity across five major therapeutic clusters in the retrieved CeD dataset, reflecting commercial IP investment and development-stage signals.
Clinical Translation Signal Strength by Program
Inferred clinical-stage readiness based on dosing specificity, jurisdictional breadth, named strains/compounds, and pharmacodynamic endpoint disclosure in retrieved patent filings.
Key IP Holders by Therapeutic Cluster
Patent activity substantially exceeds academic literature in this dataset, reflecting a predominantly commercially driven innovation landscape. Academic activity is more concentrated in diagnostics and biomarkers.
| Assignee | Target / Modality | Key Jurisdictions | Filing Period | Stage (Inferred) |
|---|---|---|---|---|
| Amgen Inc. | Anti-IL-15 antibody (CeD, RCD, NCGS) | US, CA, WO, AU, EP, IN, MX | 2017–2024 | Clinical Signals |
| Cephalon Inc. (Teva) | Anti-IL-15 DISC0280 (free IL-15 + IL-15/Rα complex) | EP, WO | 2018–2019 | Active EP |
| Intrexon Actobiotics / Precigen ActoBio | L. lactis IL-10 + gliadin antigen co-delivery (SAGX0868) | WO, CA, IN, AU, US, JP, KR, CN | 2021–2023 | Clinical Signals |
| Dr. Falk Pharma GmbH | TG2 inhibitor (HLA-stratified dosing, 100 mg/day) | WO | 2025 | Early Clinical |
| Immusant Inc. | Three-peptide DQ2 vaccine (DQ2-α-I, II, III epitopes) | EP, NZ, HU, IN, WO, US | 2011–2016 | Clinical (CCL20 endpoint) |
| DBV Technologies | Epicutaneous gliadin patch immunotherapy | WO | 2025 | Late Preclinical |
| Chugai Seiyaku | Anti-HLA-DQ2.5 antibody (gluten-peptide complex selective) | IL | 2023 | Preclinical |
| Nogra Pharma Limited | SMAD7 antisense oligonucleotide + TGF-β biomarker | WO, US, CA | 2017–2021 | US/CA Inactive |
Track Legal Status Changes Across All CeD Patent Families
PatSnap Eureka monitors jurisdictional status, opposition filings, and assignment changes in real time for every patent in the pipeline.
Strategic Implications for CeD Drug Development
IP-derived signals for R&D strategy, competitive positioning, and partnership identification across the celiac disease pipeline.
TG2 Inhibition: Most Upstream Mechanistic Intervention
TG2 inhibition represents the most mechanistically targeted upstream intervention in this dataset, interrupting deamidation before adaptive immune activation. Dr. Falk Pharma's active 2025 WO filing with HLA-stratified dosing signals this modality is entering or is in clinical evaluation. IP strategists should monitor divisional filings and freedom-to-operate relative to the tTG2 substrate-binding active site. The PatSnap analytics platform enables real-time monitoring of divisional filings.
Amgen IL-15 Estate: Dominant Jurisdictional Coverage
Amgen's anti-IL-15 IP estate is the most jurisdictionally expansive in this dataset for a single biological target, with active filings across 6+ territories including an active 2024 MX filing. This positions IL-15 blockade as a near-term clinical candidate for RCD, where the unmet need is greatest. Competing anti-IL-15 approaches (Cephalon/Teva) appear to have overlapping but mechanistically distinct epitope coverage — free IL-15 versus the IL-15/IL-15Rα complex.
Antigen-Specific Tolerance: High-Activity, Differentiation Critical
Antigen-specific tolerance induction through multiple delivery platforms — subcutaneous peptide, epicutaneous patch, nanoparticles, engineered microbes — is a high-activity area with at least 5 distinct assignees. Differentiation will likely hinge on epitope breadth (DQ2 vs. DQ8 coverage), route of administration, and durability of tolerance induction. Developers should explore PatSnap's life sciences intelligence tools for epitope landscape mapping.
Refractory CeD: Highest Unmet Need, Elevated Evidence Thresholds
Refractory celiac disease (Types I and II) is the highest-risk unmet need, with multiple modalities specifically targeting this population — KIR3DL2 (Innate Pharma), JAK inhibitors (University of California), and anti-IL-15 antibodies (Amgen). Developers entering this space should note the small patient population and elevated regulatory-evidence thresholds for demonstrating mucosal healing. The NIH and EMA have published guidance on rare autoimmune disease development pathways.
Celiac Disease Drug Pipeline — Key Questions Answered
The only current standard of care for celiac disease is a lifelong gluten-free diet (GFD). The absence of disease-modifying pharmacotherapy has driven extensive IP and academic innovation across multiple mechanistic axes.
TG2 deamidates glutamine residues in gliadin peptides, creating high-affinity HLA-DQ2/DQ8 ligands. Inhibiting TG2 would theoretically interrupt this early step in the pathogenic cascade before adaptive immune activation. The Dr. Falk Pharma patent provides transcriptomic evidence that TG2 inhibition suppresses virtually all gluten-induced mucosal gene expression changes at 100 mg/day.
IL-15 is a cytokine overexpressed in lamina propria and intestinal epithelium of active celiac disease patients, correlated with mucosal damage severity. IL-15 is described as a master cytokine driving intraepithelial lymphocyte (IEL) expansion and mucosal damage in CeD and refractory CeD (RCD). Mouse models with intestinal epithelial IL-15 overexpression recapitulate a celiac-like enteropathy.
Amgen Inc. is the dominant IP holder for anti-IL-15 in CeD, with at least 6 patent filings across US, CA, WO, AU, EP, IN, MX jurisdictions from 2017 to 2024. Activity spans CeD, RCD, and non-celiac gluten sensitivity (NCGS). Cephalon Inc. (a Teva subsidiary) also holds active EP and WO filings covering anti-IL-15 antibody DISC0280.
Antigen-specific peptide immunotherapy involves tolerogenic peptide vaccination strategies targeting HLA-DQ2/DQ8-restricted gluten epitopes, with the mechanistic goal of inducing immune tolerance to pathogenic gliadin peptides. Multiple assignees pursue this approach including Immusant (subcutaneous peptide), DBV Technologies (epicutaneous skin patch), and Cour Pharmaceuticals (tolerogenic nanoparticles).
Refractory celiac disease (Types I and II) is the highest-risk unmet need in the celiac disease space. Multiple modalities specifically target this population including KIR3DL2-targeting agents (Innate Pharma), JAK inhibitors (University of California), and anti-IL-15 antibodies (Amgen). JAK inhibitors are also positioned as lymphoma-preventive agents in RCD Type II — an unmet need not addressed by TG2 inhibitors or antigen-specific therapies.
Still have questions about the celiac disease drug pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About CeD PatentsAccelerate Your Celiac Disease Drug Discovery with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to navigate complex autoimmune pipelines, identify white-space opportunities, and monitor competitor IP in real time.
References
- Method for personalized therapy of celiac disease — Dr. Falk Pharma GmbH, 2025, WO [Patent]
- Diagnosis and treatment of gluten-induced autoimmune diseases — University of Debrecen, 2018, EP [Patent]
- Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease — Amgen Inc., 2019, EP [Patent]
- Anti-IL-15 antibody for treatment of celiac disease, non-celiac gluten sensitivity and refractory celiac disease — Amgen Inc., 2024, MX [Patent]
- Antibodies that specifically bind to human IL-15 and uses thereof — Cephalon Inc., 2018, WO [Patent]
- Antibodies that specifically bind to human IL-15 and uses thereof — Cephalon Inc., 2019, EP [Patent]
- Compositions comprising high molecular weight synthetic polymers for reducing deleterious effects of gluten — Valorisation-Recherche, 2016, IL [Patent]
- Compositions and methods for treatment of celiac disease — Immusant Inc., 2011, EP [Patent]
- Epitopes related to coeliac disease — BTG International Limited, 2010, NZ [Patent]
- Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease — DBV Technologies, 2025, WO [Patent]
- Immune modified particles encapsulated gliadin antigenic epitopes for treating refractory celiac disease — Cour Pharmaceuticals, 2020, IL [Patent]
- Treatment of celiac disease — Intrexon Actobiotics NV / Precigen ActoBio, 2021, WO [Patent]
- Composition and methods of treating inflammatory and autoimmune diseases — Tiziana Life Sciences PLC, 2022, US [Patent]
- Compositions and methods for treating celiac disease — University of California, 2022, WO [Patent]
- Treatment of celiac disease — Innate Pharma, 2016, WO [Patent]
- Methods of treating celiac disease using SMAD7 inhibition — Nogra Pharma Limited, 2017, WO [Patent]
- Anti-HLA-DQ2.5 antibody and its use for the treatment of celiac disease — Chugai Seiyaku, 2023, IL [Patent]
- Use of activators of the aryl hydrocarbon receptor for treating gluten-induced gastrointestinal diseases — INRAE, 2020, CA [Patent]
- National Institute of Allergy and Infectious Diseases (NIAID) — Autoimmune Disease Research
- European Medicines Agency (EMA) — Rare Disease Guidance
- World Health Organization (WHO) — Autoimmune Disease Burden
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.